UAMS Myeloma Institute Presentations

Click here for Dr. Bart Barlogie's 2009 presentation of the Long-Term Follow-Up of Autotransplant Trials for Multiple Myeloma. 2009 Annual Meeting, American Society of Clinical Oncology (ASCO).

Click here to view Clinical Research in Multiple Myeloma: Linking Outcomes to Genomics of Both Tumor & Normal Host Cells.  April 2009, American Association for Cancer Research Annual Meeting.

Click here for The Myth of Incurability, Dr. Bart Barlogie’s 2008 ASCO meeting presentation. Click here for summary of the presentation, “Do total therapy protocols broach the unthinkable – a cure?,” which is found in The Oncology Report.

Click here to view Dr. Barlogie’s presentation at the 2008 ASH meeting: 90% CR Sustained 4 Years After Onset of CR in Gene Array-Defined Low-Risk Myeloma Treated With Total Therapy 3: Basis for Risk-Adapted TT4 AND TT5.

Click here to view Hematologic Malignancies in the Aging Population: Biology, Molecular Prognostic Markers and Novel Treatment Strategies.

Click here to view Total Therapy for Multiple Myeloma: Evolution from Palliation to Cure during 20 Years of Clinical Research.

Listen to presentations from Myeloma Institute faculty at the June 2007 XIth International Myeloma Workshop:

John Shaughnessy, PhD
Towards a Molecular-Based Risk Stratification of Multiple Myeloma

Joshua Epstein, DSc
The Scid-hu model for Multiple Myeloma

Bart Barlogie, MD, PhD,
Debate II - Should autologous transplant be part of the primary treatment in mm? YES

Having problems with the site? E-mail the Webmaster.
Copyright 2002-2005, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Terms and Conditions of Use

The information on the Myeloma Institute web site is not intended as a substitute for professional medical attention. The information is intended only as an aid in understanding current medical knowledge. A physician should always be consulted for any health concern or medical condition. The Myeloma Institute web site provides links to other organizations as a service to our readers. The Myeloma Institute is not responsible for the information provided on other web sites.